MX2016014704A - Sales farmaceuticamente aceptables de enantiomeros de pirlindol para utilizarse en medicina. - Google Patents

Sales farmaceuticamente aceptables de enantiomeros de pirlindol para utilizarse en medicina.

Info

Publication number
MX2016014704A
MX2016014704A MX2016014704A MX2016014704A MX2016014704A MX 2016014704 A MX2016014704 A MX 2016014704A MX 2016014704 A MX2016014704 A MX 2016014704A MX 2016014704 A MX2016014704 A MX 2016014704A MX 2016014704 A MX2016014704 A MX 2016014704A
Authority
MX
Mexico
Prior art keywords
medicine
pharmaceutically acceptable
acceptable salts
pirlindole
pirlindole enantiomers
Prior art date
Application number
MX2016014704A
Other languages
English (en)
Inventor
Eugénio Pardal Filipe Augusto
Marques Almeida Pecorelli Susana
Alberto Eufrásico CASIMIRO CAIXADO Carlos
Filipe Eufrásio Pedroso Pedro
Sofia Da Conceição Lopes Ana
Carlos Ramos DAMIL João
Paulo De Lacerda E Oliveira Santos Pedro
Original Assignee
Tecnimede Soc Tecnico-Medicinal S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Soc Tecnico-Medicinal S A filed Critical Tecnimede Soc Tecnico-Medicinal S A
Publication of MX2016014704A publication Critical patent/MX2016014704A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona sales farmacéuticamente aceptables de los compuestos (r)-pirlindol y (S)-pirlindol enantioméricamente puros que tienen un perfil de biodisponibilidad incrementado para utilizarse en medicina.
MX2016014704A 2014-05-09 2014-05-09 Sales farmaceuticamente aceptables de enantiomeros de pirlindol para utilizarse en medicina. MX2016014704A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000026 WO2015171002A1 (en) 2014-05-09 2014-05-09 Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine

Publications (1)

Publication Number Publication Date
MX2016014704A true MX2016014704A (es) 2017-05-23

Family

ID=50819928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014704A MX2016014704A (es) 2014-05-09 2014-05-09 Sales farmaceuticamente aceptables de enantiomeros de pirlindol para utilizarse en medicina.

Country Status (18)

Country Link
US (1) US10226460B2 (es)
EP (2) EP3831385B1 (es)
JP (1) JP6400121B2 (es)
KR (1) KR102276281B1 (es)
CN (1) CN106413713B (es)
AU (1) AU2014393487B2 (es)
CA (1) CA2948595C (es)
EC (1) ECSP16086196A (es)
IL (1) IL248852B (es)
MA (1) MA39450B2 (es)
MX (1) MX2016014704A (es)
NZ (1) NZ726127A (es)
PH (1) PH12016502235A1 (es)
RU (1) RU2706688C2 (es)
SA (1) SA516380258B1 (es)
TN (1) TN2016000495A1 (es)
UA (1) UA118587C2 (es)
WO (1) WO2015171002A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3057589T1 (sl) * 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (s)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini
EP3054950B1 (en) * 2014-05-09 2017-08-02 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
EP3392250A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of piperazine ring for the synthesis of pyrazinocarbazole derivatives
EP3392251A1 (en) * 2017-04-21 2018-10-24 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Process for the preparation of pirlindole enantiomers and its salts

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO166131C (no) 1985-06-20 1991-06-05 Daiichi Seiyaku Co Analogifremgangsmaate for fremstilling av s(-)-pyridobenzoksazinforbindelser.
AU2003284005B2 (en) * 2002-10-03 2009-12-17 Forest Laboratories Holdings Limited Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
AU2009324495B2 (en) * 2008-12-11 2015-12-24 Biovista, Inc. Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
US20150250808A1 (en) * 2012-10-15 2015-09-10 Vojo P. Deretic Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
SI3057589T1 (sl) * 2014-05-09 2017-12-29 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (s)-pirindol in njegove farmacevtsko sprejemljive soli za uporabo v medicini
EP3054950B1 (en) * 2014-05-09 2017-08-02 Tecnimede-Sociedade Tecnico-Medicinal, S.A. (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
KR102258709B1 (ko) * 2014-05-09 2021-06-01 테크니메데 소시에다데 테크니코-메디시날 에스.에이. 광학 활성적인 펄린돌 광학이성질체 및 그의 염의 제조방법

Also Published As

Publication number Publication date
KR102276281B1 (ko) 2021-07-13
AU2014393487B2 (en) 2020-01-02
EP3139926A1 (en) 2017-03-15
CN106413713B (zh) 2020-07-14
MA39450B2 (fr) 2021-10-29
RU2016148174A (ru) 2018-06-14
NZ726127A (en) 2019-03-29
US20170143710A1 (en) 2017-05-25
CA2948595A1 (en) 2015-11-12
SA516380258B1 (ar) 2019-11-04
KR20170002433A (ko) 2017-01-06
UA118587C2 (uk) 2019-02-11
EP3831385B1 (en) 2024-07-10
JP2017514882A (ja) 2017-06-08
RU2706688C2 (ru) 2019-11-20
ECSP16086196A (es) 2017-02-24
EP3831385A1 (en) 2021-06-09
CN106413713A (zh) 2017-02-15
PH12016502235A1 (en) 2017-01-09
JP6400121B2 (ja) 2018-10-03
IL248852A0 (en) 2017-01-31
MA39450A1 (fr) 2017-08-31
CA2948595C (en) 2021-07-13
TN2016000495A1 (en) 2018-04-04
IL248852B (en) 2020-05-31
WO2015171002A1 (en) 2015-11-12
US10226460B2 (en) 2019-03-12
RU2016148174A3 (es) 2018-06-14
AU2014393487A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
IL247901A0 (en) Additional salts of (s)-2-(1-(6-amino-5-cyanopyrimidine-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1 ,2,4]triazine-5-carbonitrile
EP3256218A4 (en) Kdm1a inhibitors for the treatment of disease
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
EP3302485A4 (en) CERDULATINIB FOR THE TREATMENT OF B-CELL MALIGNOMES
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
EP3528737A4 (en) MEDICAL STAND
PH12016502235A1 (en) Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
PH12016502234B1 (en) Process for obtaining optically active pirlindole enantiomers and salts thereof
HK1251476A1 (zh) 用於治療癌症的氨基硫羥酸酯化合物或其藥學上可接受的鹽
ZA201907515B (en) Process for the preparation of pirlindole enantiomers and its salts
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
RS62667B1 (sr) Proces za pripremu pirlindol enantiomera i njegovih soli
PL3612535T3 (pl) Sposób otrzymywania enancjomerów pirlindolu i jego soli
EP3122356A4 (en) Treatment of parkinson's disease through arfgap1 inhibition using substituted piperazine derivatives
EP3138560A4 (en) Drug for treatment of tinnitus patients
EP3138559A4 (en) Drug for treatment of tinnitus patients

Legal Events

Date Code Title Description
FG Grant or registration